1. Addressing Iron Deficiency in Chronic HF

3. Introduction

4. Prevalence of ID in Patients With HF

5. Prevalence of ID in Patients With HF (cont)

6. Importance of Iron for Functioning and Survival

7. Prevalence of ID According to NYHA FC

8. Etiology of ID in HF

9. Definition of ID

10. Blood Tests Used to Diagnose ID

11. Definition of ID (cont)

12. Screening for ID in Patients With HF

13. Symptoms of ID in Patients With HF

14. FCM: Summary of Clinical Evidence

15. Oral Iron Supplementation

16. High-Dose Oral Iron in HFrEF: Results of the IRONOUT HF Trial

17. Lack of Efficacy of Oral Iron in IRONOUT HF Study: One Explanation

18. Detrimental Effects of ID

19. FERRIC-HF II Study

20. Efficacy of FCM Stratified According to the Presence of Anemia

21. CONFIRM-HF: Time to First Hospitalization Due to Worsening HF

22. Effect of FCM on Patient Outcomes: An Individual Patient Data Meta-Analysis

23. CVOTs in Patients Treated With FCM

24. Prevalence of Anemia, ID, and ID Anemia in Renal Transplant Recipients

25. Impact of FCM on Renal Function: The FAIR-HF Study

26. Overall FCM Is Safe and Well Tolerated

27. FCM: Safety and Tolerability

28. FCM: Safety and Tolerability (cont)

29. FCM: Safety and Tolerability (cont)

30. Replenishing Iron Stores: Monitoring and Follow-Up

31. Iron Replacement in Patients With HFpEF

32. FAIR-HFpEF

33. Management of ID in Patients With HF: Practical Considerations

34. Management of ID in Patients With HF: Practical Considerations (cont)

35. Absolute ID

36. Evaluation of ID in Patients With HF

37. Management of ID in Patients With HF: A Multidisciplinary Team Approach

38. Summary and Conclusions

39. Abbreviations

40. Abbreviations (cont)